| Name | Title | Contact Details |
|---|---|---|
Henry Capello |
VP, Chief Information Security Officer | Profile |
Adam Wasylyshyn |
Senior Vice President and Chief Information Officer | Profile |
Kevin Boyle |
Senior Vice President, Chief Technology Officer and Member of the Management Committee | Profile |
Ricardo Johnson |
VP, Chief Information Security Officer | Profile |
Recovery Force is an innovative medical device company providing healthcare professionals, patients, and athletes with a next-generation mobile compression solution for enhancing circulation. The company has developed a platform technology with the ability to embed shape-changing memory fibers into various types of garments and footwear to produce therapeutic compressions. Recovery Force`s portfolio includes medical devices that will reduce post-operative pain, swelling and wound healing time; treat chronic lymphedema; prevent blood clots (DVT); and alleviate joint pain and sore muscles. The same technology used in healthcare is also available to sports enthusiasts and athletes, providing enhanced circulation during warm-up and recovery to achieve optimal performance.
Nuo Therapeutics, Inc. (formerly Cytomedix, Inc.) is a biomedical company that develops and commercializes individualized wound care therapies that harness a patient’s innate regenerative ability to stimulate wound healing. The Company’s flagship product, Aurix is a biodynamic hematogel derived from the patient’s own platelets and plasma, which is used at the point-of-care to jumpstart the natural healing process in a broad range of chronic wounds, including diabetic foot ulcers, venous leg ulcers and pressure ulcers (bedsores).
Lyntek Medical Technologies is a Draper, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Global Medical Systems is a Costa Mesa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Miromatrix Medical technology has the potential to enable the creation of fully biological replacement organs for the human body. In addition to the Company’s internal efforts focused on the development of its first product – a biological mesh for hernia repair – scientists around the globe are working with the Company’s technology and are taking critical steps toward the creation of human organs including the liver, lung, kidney, pancreas and heart. While our biological mesh development program has been conducted internally, our intent is for current and future products to be developed both at Miromatrix and in partnership with the best among those external groups already working with our technology in order to utilize this pre-existing expertise to develop individual products in the most efficacious, cost-effective and timely way possible.